BUZZ-肥胖症药物试验加速，Viking Therapeutics 公司业绩大增

Reuters07-25

((自动化翻译由路透提供，请见免责声明 ))

7月25日 - ** Viking Therapeutics 股价盘前上涨20.15%至60.57美元

** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。

** 在中期试验 (link) 中，该药物显示体重最多可减轻 ~15

** Truist表示，这将缩短约12个月的上市时间

** 在未来的试验中，将对每月一次的皮下注射药物剂量进行评估。

** 公司还预计在 2024 年晚些时候开始口服版药物的中期试验

** 最令人惊讶的最新进展是，该公司已经完成了60毫克和80毫克剂量口服药物的患者用药，并正在对100毫克剂量进行评估，这意味着该药物具有良好的耐受性 - Truist

** 截至上一交易日收盘，该公司股价已上涨一倍多

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2454475158?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-25 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454475158","market":"us","top_or_hot":-1,"title":"BUZZ-肥胖症药物试验加速，Viking Therapeutics 公司业绩大增","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    7月25日 - ** Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>   股价盘前上涨20.15%至60.57美元</p><p>** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。</p><p>** 在中期试验 (link) 中，该药物显示体重最多可减轻 ~15</p><p>** Truist表示，这将缩短约12个月的上市时间</p><p>** 在未来的试验中，将对每月一次的皮下注射药物剂量进行评估。</p><p>** 公司还预计在 2024 年晚些时候开始口服版药物的中期试验</p><p>** 最令人惊讶的最新进展是，该公司已经完成了60毫克和80毫克剂量口服药物的患者用药，并正在对100毫克剂量进行评估，这意味着该药物具有良好的耐受性 - Truist</p><p>** 截至上一交易日收盘，该公司股价已上涨一倍多 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-肥胖症药物试验加速，Viking Therapeutics 公司业绩大增</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-肥胖症药物试验加速，Viking Therapeutics 公司业绩大增\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-25 17:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    7月25日 - ** Viking Therapeutics   股价盘前上涨20.15%至60.57美元** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。** 在中期试验 (link) 中，该药物显示体重最多可减轻 ~15** Truist表示，这将缩短约12个月的上市时间** 在未来的试验中，将对...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2454475158","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454475158","pubTimestamp":1721901142,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    7月25日 - ** Viking Therapeutics   股价盘前上涨20.15%至60.57美元** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。** 在中期试验  中，该药物显示体重最多可减轻 ~15** Truist表示，这将缩短约12个月的上市时间** 在未来的试验中，将对每月一次的皮下注射药物剂量进行评估。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4581":"高盛持仓","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BUZZ":"VanEck Social Sentiment ETF","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4516":"特朗普概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LENZ":"Therapeutics","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","LU0385154629.USD":"贝莱德营养科学基金A2","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4534":"瑞士信贷持仓","LU0079474960.USD":"联博美国增长基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4007":"制药","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC"},"translate_title":"BUZZ-Viking Therapeutics' performance surges as obesity drug trials accelerate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"LENZ":1,"VKTX":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    7月25日 - ** Viking Therapeutics   股价盘前上涨20.15%至60.57美元** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。** 在中期试验 (link) 中，该药物显示体重最多可减轻 ~15** Truist表示，这将缩短约12个月的上市时间** 在未来的试验中，将对每月一次的皮下注射药物剂量进行评估。** 公司还预计在 2024 年晚些时候开始口服版药物的中期试验** 最令人惊讶的最新进展是，该公司已经完成了60毫克和80毫克剂量口服药物的患者用药，并正在对100毫克剂量进行评估，这意味着该药物具有良好的耐受性 - Truist** 截至上一交易日收盘，该公司股价已上涨一倍多","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454475158"}